refractory diabetic macular edema
Conditions
Interventions
Monotherapy group:switch to other anti -VEGF
Combination group:intravitreal dexamethasone implant combined with anti-VEGF
Sponsors
Nanning Aier Eye Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Optical coherence tomography (OCT) confirmed the presence of hard retinal exudation and thickening involving or threatening the macular center, and then retinal effusion in the macular region; (2) foveal retinal thickness (CRT) >300µm; (3) After receiving at least three monthly intravitreal anti-VEGF injections (leizumab, Compaximab, or arbocept injection), OCT still showed a sustained increase in subretinal fluid or interretinal fluid or a decrease in CRT < 10% from baseline; (4) have not received Audix implantation or other hormone drug intravitreal injection therapy before; (5) For patients with cataract, macular anterior membrane, proliferative DR And other visual impairment, cataract surgery + vitrectomy +/ or -macular anterior membrane stripping + total retinal laser photocoagulation should be performed before intraocular injection
Exclusion criteria
Exclusion criteria: (1) iris neovascularization, glaucoma and inadequate control of two local glaucoma drugs; (2) There have been other ocular fundus diseases that affect vision in the past, such as age-related macular degeneration, retinal detachment, macular holes and high myopia; (3) Corneal leukoplakia affected the observation of fundus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| best corrected visual acuity;central macular thickness; | — |
Secondary
| Measure | Time frame |
|---|---|
| intraocular pressure ;the injection number;Cataract surgery rate; | — |
Countries
China
Contacts
Public ContactLiang Xuemei
Nanning Aier Eye Hospital
Outcome results
None listed